- Report
- March 2021
- 207 Pages
Global
From €1138EUR$1,250USD£975GBP
€2275EUR$2,500USD£1,951GBP
- Report
- August 2022
- 119 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Drug Pipelines
- April 2024
- 40 Pages
Global
From €1138EUR$1,250USD£975GBP
- Report
- November 2023
- 353 Pages
Global
From €8646EUR$9,500USD£7,412GBP
- Report
- April 2023
- 180 Pages
Global
From €6826EUR$7,500USD£5,852GBP
- Drug Pipelines
- January 2023
- 30 Pages
United States
From €2503EUR$2,750USD£2,146GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2503EUR$2,750USD£2,146GBP
- Drug Pipelines
- January 2023
- 30 Pages
United States
From €2503EUR$2,750USD£2,146GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2503EUR$2,750USD£2,146GBP
- Drug Pipelines
- January 2023
- 30 Pages
United States
From €2503EUR$2,750USD£2,146GBP
- Report
- March 2024
- 85 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- January 2025
- 93 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Book
- July 2023
- 320 Pages
Fulvestrant is a type of breast cancer drug used to treat hormone receptor-positive metastatic breast cancer. It is a type of hormone therapy, which works by blocking the effects of the hormone estrogen on cancer cells. Fulvestrant is administered as an intramuscular injection, and is typically used in combination with other treatments such as chemotherapy. It is used in postmenopausal women who have already been treated with other hormone therapies, such as tamoxifen.
Fulvestrant is a relatively new drug, and is still being studied in clinical trials. It has been found to be effective in treating certain types of breast cancer, and is generally well-tolerated by patients. It is also being studied for its potential to be used in combination with other treatments, such as immunotherapy.
Some companies in the Fulvestrant market include AstraZeneca, Pfizer, Novartis, and Eli Lilly. Show Less Read more
